Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

• Status: Recruiting
• Trial end date: 2023-10-01

Summary

The purpose of this study is to study the impact of stem cell dose on outcome after autologous transplant.

• Phase: Phase 2

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborators: Columbia University; Medical College of Wisconsin; Montefiore Medical Center; NorthShore University HealthSystem; Sanofi; SCRI Development Innovations, LLC; The Cleveland Clinic; University Hospitals Seidman Cancer Center; University of Nebraska; University of Rochester; Weill Medical College of Cornell University
• Treatments: Carmustine; Cytarabine; Etoposide; Etoposide phosphate; JM 3100; Melphalan; Plerixafor